The Role of MAPK-Signalling in Pancreatic Neuroendocrine Cancer Abstract #1737

Introduction: Upon diagnosis, 65% of pNET patients suffer from metastatic or locally unresectable disease. The receptor tyrosine kinase inhibitor sunitinib and the mTOR inhibitor everolimus have set precedence for successful targeted therapies in pNET disease. However, response prediction and treatment alternatives still do not meet medical needs. Recent studies revealed mutations in RAS oncogenes in a fraction of tumours, emphasising a potential role of the MAPK pathway as therapeutic target.
Aim(s): To study the consequences of pharmacologic inactivation of MEK or ERK kinases in pNET cells.
Materials and methods: BON-1 and QGP-1 cell lines are treated with either MEK or ERK inhibitors. Live cell analysis is performed to determine efficacy and growth inhibition. Induction of apoptosis is shown by cleaved caspase-3 and cell cycle regulation is analysed by flow cytometry. Changes in the MAPK and mTOR signalling network are determined by western blots and multiplex immunoassays.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Julia Hoffmann

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...
#2693 The Distinctive Character of Micro-Vasculature and Immune Cell Infiltration in Cystic Pancreatic Neuroendocrine Tumors
Introduction: Hypervascularity is main character of pancreatic neuroendocrine tumors (PanNETs), cystic PanNET (CPanNET) are unique type of PanNETs for which the microenvironment remains unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Heli Gao
Authors: Gao H, ...
#2705 Increased Autophagy/Mitophagy Levels in Pancreatic Neuroendocrine Neoplasms
Introduction: Autophagy and mitophagy are key homeostatic machineries linked to cancer development and drug resistance.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD, PhD Kosmas Daskalakis
#2707 Investigating the Crosstalk between MEN1, p53 and Notch Reveals Biomarkers of Formation of Primary Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNETs) comprise a heterogeneous group of endocrine tumors. Previous studies showed that mutations of p53 are extremely rare; whereas genetic changes of MEN1 frequently occur and are correlated with poor prognosis in PNET. Still, their roles in tumorigenesis remain elusive.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Ylenia Capodanno
#2729 Survival of Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in a Single Institute in North Africa over the Last 16 Years
Introduction: Because of the low incidence, nonspecific symptoms at presentation, lack of awareness, and non-uniform classifications, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) remains a poorly understood disease, and delayed diagnosis is common among patients with GEP-NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Imen Harhira